英特集团分析师会议-20251105

Group 1: Research Basic Information - The research object is Intco Group, belonging to the pharmaceutical commerce industry, with a reception time of November 5, 2025. The listed company's reception staff includes the board secretary Tan Jiang and the securities affairs representative Qiu Li [17] Group 2: Detailed Research Institutions - The reception object types include institutional relevant personnel, and the specific reception object is Shibang Fund [20] Group 3: Company's Main Business and Operating Model - The company's main business is the wholesale and retail of drugs, traditional Chinese medicine, biological products, and medical devices. The operating model is to purchase products from upstream pharmaceutical production or supply enterprises and then wholesale them to downstream medical institutions, pharmacies, distributors, etc., and also sell directly to consumers through retail terminals [24] Group 4: Company's Acquisition of Huatong Pharmaceutical - Huatong Pharmaceutical has completed the industrial and commercial change registration procedures for relevant matters such as equity transfer and has become a wholly - owned subsidiary of Intco Pharmaceutical. Its wholesale business has obvious advantages in the primary public medical market, and its retail segment Huatong Chain is among the top 100 pharmaceutical retail enterprises, forming high synergy with the company's existing business. The acquisition helps improve the company's market share in Zhejiang, enhance bargaining power with upstream suppliers and influence on terminal consumers [25] Group 5: Company's Accounts Receivable Collection - The company's accounts receivable collection cycle is generally stable, with differences in different regions in Zhejiang and among different types of customers. The company attaches importance to the management of accounts receivable turnover and has established a credit risk management system covering the entire business process [26][27] Group 6: Shitang Pharmaceutical Industrial Park - The wholly - owned subsidiary Zhejiang Intco Smart Network Technology Co., Ltd. won the right to use 79,357 square meters (119.035 mu) of state - owned construction land in the Shitang block of the Hanggang unit in Gongshu District at the end of July 2024 for the investment and construction of the Shitang Pharmaceutical Industrial Park project [28]